Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.2M Sell
299,649
-25,821
-8% -$1.72M 0.03% 418
2026
Q1
$20.4M Buy
325,470
+11,017
+4% +$767K 0.03% 395
2025
Q4
$20.9M Buy
314,453
+8,294
+3% +$536K 0.04% 382
2025
Q3
$20.6M Buy
306,159
+14,697
+5% +$1.16M 0.04% 374
2025
Q2
$25.4M Buy
291,462
+18,667
+7% +$1.46M 0.05% 311
2025
Q1
$18.6M Buy
272,795
+31,893
+13% +$2.6M 0.04% 355
2024
Q4
$18.7M Buy
240,902
+63,622
+36% +$4.71M 0.05% 336
2024
Q3
$11.9M Buy
177,280
+4,405
+3% +$362K 0.03% 404
2024
Q2
$19.6M Buy
172,875
+42,620
+33% +$5.39M 0.05% 351
2024
Q1
$18.1M Buy
130,255
+33,423
+35% +$4.2M 0.06% 355
2023
Q4
$12M Sell
96,832
-140,565
-59% -$14.4M 0.04% 423
2023
Q3
$22.1M Buy
237,397
+33,441
+16% +$3.77M 0.09% 283
2023
Q2
$26.2M Buy
203,956
+96,413
+90% +$11.7M 0.11% 227
2023
Q1
$12.5M Sell
107,543
-37,230
-26% -$4.17M 0.06% 426
2022
Q4
$16.4M Sell
144,773
-120,374
-45% -$13.2M 0.08% 349
2022
Q3
$21.4M Sell
265,147
-26,403
-9% -$2.24M 0.12% 215
2022
Q2
$21.7M Buy
291,550
+96,410
+49% +$8.8M 0.12% 230
2022
Q1
$25M Buy
195,140
+71,264
+58% +$7.8M 0.12% 183
2021
Q4
$16.6M Sell
123,876
-1,168
-0.9% -$168K 0.07% 273
2021
Q3
$17.1M Sell
125,044
-4,888
-4% -$616K 0.08% 259
2021
Q2
$13.9M Buy
129,932
+6,572
+5% +$631K 0.06% 304
2021
Q1
$11.1M Sell
123,360
-692
-0.6% -$65K 0.05% 317
2020
Q4
$11.5M Buy
124,052
+5,264
+4% +$470K 0.06% 298
2020
Q3
$12.2M Sell
118,788
-3,620
-3% -$378K 0.07% 236
2020
Q2
$12.4M Sell
122,408
-59,120
-33% -$5.29M 0.08% 218
2020
Q1
$12.2M Buy
181,528
+54,316
+43% +$3.38M 0.09% 191
2019
Q4
$6.96M Sell
127,212
-184
-0.1% -$8.73K 0.04% 371
2019
Q3
$4.75M Sell
127,396
-1,656
-1% -$64.3K 0.03% 439
2019
Q2
$4.83M Sell
129,052
-2,836
-2% -$89.1K 0.03% 460
2019
Q1
$3.93M Buy
+131,888
New +$4.63M 0.03% 522

Other funds holding DXCM

Aviva's DXCM Position: Q2 2026 in Review

Aviva reduced its DexCom (DXCM) stake by 7.9% in Q2 2026, selling an estimated $1.72M and leaving 299,649 shares worth $20.2M. The position accounts for 0.03% of the portfolio, ranked #418.

Aviva first reported a position in DXCM in Q1 2019 and has held it in 30 quarters since. The position peaked at $26.2M in Q2 2023. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Aviva held 299,649 shares of DexCom worth $20.2M as of Q2 2026.
  • Aviva sold 25,821 DexCom shares in Q2 2026, an estimated $1.72M.
  • DexCom made up 0.03% of Aviva's portfolio in Q2 2026, its #418 holding.
  • Aviva first reported a position in DexCom in Q1 2019 and has held it in 30 quarters since.
  • Aviva's DexCom position peaked at $26.2M in Q2 2023.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.